Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethopropazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | BCHE | P06276 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ACHE | P22303 | 3/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethopropazine SCHEMBL29426328 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Ethopropazine SCHEMBL34046 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Ethopropazine SCHEMBL30516992 | 0.98 | ALDH1A1 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Ethopropazine SCHEMBL123703 | 0.98 | ALDH1A1 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Ethopropazine SCHEMBL2316087 | 0.98 | CYP2D6 (0.97) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Ethopropazine SCHEMBL123702 | 0.98 | ALDH1A1 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Ethopropazine SCHEMBL10616920 | 0.97 | ALDH1A1 (0.97) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Ethopropazine SCHEMBL719170 | 0.97 | CYP2D6 (0.94) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Ethopropazine SCHEMBL10626220 | 0.95 | ALDH1A1 (0.94) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Ethopropazine SCHEMBL6943819 | 0.93 | ALDH1A1 (0.89) | CYP2D6CHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17127 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250302814-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2025-10-02 | — | — | US | claimed |
| US-20250241933-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) | 2025-07-31 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4543431-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) (US) | 2025-04-30 | — | — | EP | claimed |
| WO-1993022293-A1 | 1-PIPERAZINO-1,2-DIHYDROINDENE DERIVATIVES | H. LUNDBECK A/S (DK) | 1993-11-11 | — | — | WO | claimed |
| US-5221536-A | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement | ALZA CORPORATION (US) | 1993-06-22 | — | — | US | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
| US-5190763-A | DOSAGE FORM INDICATED FOR THE MANAGEMENT OF ABNORMAL POSTURE, TREMOR AND INVOLUNTARY MOVEMENT | ALZA CORPORATION (US) | 1993-03-02 | — | — | US | claimed |
| EP-0527835-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT. | ALZA CORP (US) | 1993-02-24 | — | — | EP | claimed |
| WO-1992008667-A1 | VEHICLE-POWERED ELEVATED PARKING SYSTEM | LPD INC (US) | 1992-05-29 | — | — | WO | claimed |
| WO-1991016885-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORPORATION (US) | 1991-11-14 | — | — | WO | claimed |
| US-5057321-A | Dosage form comprising drug and maltodextrin | ALZA CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| EP-0324947-A1 | Synergistic combination of decarboxylase inhibitors and L-dopa pellets | ASTA Medica Aktiengesellschaft (DE) | 1989-07-26 | — | — | EP | claimed |
| EP-0035597-B1 | PHARMACEUTICAL PREPARATIONS | Röhm Pharma GmbH (DE) | 1984-08-01 | — | — | EP | claimed |